Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BioVie ( (BIVI) ) is now available.
On June 23, 2025, BioVie Inc. held a special meeting of stockholders to consider two key proposals. The stockholders granted the board of directors the authority to effect a reverse stock split of the company’s common stock, with a ratio between 1-for-5 and 1-for-10, to be determined by the board within a year. Additionally, stockholders approved the discretionary authority to adjourn the meeting if necessary to solicit more proxies for the reverse stock split proposal.
The most recent analyst rating on (BIVI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.
Spark’s Take on BIVI Stock
According to Spark, TipRanks’ AI Analyst, BIVI is a Underperform.
BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.
To see Spark’s full report on BIVI stock, click here.
More about BioVie
Average Trading Volume: 420,980
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.13M
For detailed information about BIVI stock, go to TipRanks’ Stock Analysis page.